CASE REPORT

CARCINOMA BREAST - DON’T MISS THE SYNCHRONOUS CARCINOMA IN THE SECOND BREAST
A. Ravikamal Kumar¹, S. V. P. L. Chandrakumar²

INTRODUCTION: Synchronous bilateral carcinoma of breast is rare about 1-2% incidence.[1] Occurrence of carcinoma in the second breast within 3 months of detection of carcinoma in the first breast or occurring simultaneously in both breasts is considered as synchronous bilateral carcinoma breast. If the carcinoma in the 2nd breast occurs more than 3 months after the occurrence of the index carcinoma it is considered as metachronous.[2,3] It's incidence is reported to be 5-6%.[1] Here we report a case of bilateral synchronous carcinoma of breast which we treated in our unit. The literature is reviewed as to it’s definition, biological behaviour, treatment and prognosis.

CASE REPORT: A 50 years old female patient presented with a lump in the left breast of 1 month duration. No history of bone pains, dyspnoea, haemoptysis and jaundice. No family history of breast carcinoma. On examination a 5 cm hard mass with irregular borders is found in the upper outer quadrant of the left breast. Clinically it is not fixed to chest wall or to pectoral muscles. No peau d’ orange or skin fixity. There were two lymphnodes palpable in the left axilla which were hard in consistency and not fixed to skin or to one another or to adjacent structures. No supraclavicular lymphnodes palpable. On examination of the right breast, an ill-defined granular mass is found in the upper and outer quadrant. No lymphnodes were palpable in the right Axilla.

Mammography showed the following findings. Lt. breast- ill-defined symmetric density with powdery microlcalkification Birad’s category V lesion. Rt. Breast- diffuse nodularity with powdery microcalcification Birad’s category V lesion. FNAC revealed duct cell carcinoma in both breasts. Blood investigations showed Hb-8gms, RBS, Blood urea, sr. creatinine Sr. alkaline phosphatase were within normal limits. Chest x-ray showed no metastasis in the lungs, ribs or pleura. U/s of abdomen showed no secondaries in liver or ascites. No bone scan was done as it was not available in govt. general hospital.

After cardiac evaluation under general anesthesia, modified radical mastectomy was done on both breasts. Post-operative recovery was uneventful. Stitch abscess occurred at one site which was dealt with. HPE of the specimens showed the following.

Left breast- 6x5x5 cm grey white irregular tumour present. Histologic features of infiltrating duct cell carcinoma along with in situ component 30% showing comedo & cribriform patterns seen. Basal cut margins showed tumour infiltration. Vascular invasion present. NBR grade II. All 9 lymphnodes showed tumour deposits.

Right breast- greyish white gritty lesion of 4x2x1 cm seen. Sections showed infiltrating duct cell carcinoma with insitu component 50% showing comedo & cribriform pattern. Margins are free. One of the axillary lymphnodes show tumour deposits. NBR score 6 grade II.

ER and PR receptors found to be negative but HER2/neu receptor is positive.
The patient was sent to chemotherapy and radiotherapy department for further treatment. She was started on chemotherapy 4 cycles of Adriamycin and cyclophosphamide followed by taxanes. While on chemotherapy after 8 months the patient developed altered sensorium and convulsions and died before CT of the brain could be done.

**DISCUSSION:** Bilateral breast carcinoma represents a small proportion of all breast carcinoma cases. Contralateral breast carcinoma can occur synchronously or metachronously. Synchronous breast carcinoma was defined as cancer diagnosed in both breasts simultaneously or within 3 months of diagnoses of first tumour. Metachronous breast cancer was defined as the one diagnosed in the contralateral breast more than 3 months after the diagnosis of the tumour in the index breast.[2,3] The reported incidence of synchronous bilateral carcinoma is approximately 1-2% and that of metachronous carcinoma is 5-6%.[1]

Is the second tumour in the contralateral breast a metastasis from the primary breast lesion i.e. index tumour or is it a second primary breast cancer developed de novo? This question is important for the clinician as in the first case only palliative care is possible but the second can be treated radically. Most of the SBBC are independent primary tumours and not due to metastasis from primary breast lesion. Features that characterise a second primary tumour are extensive in-situ component, different histologies or different degrees of differentiation between the tumours and absence of other metastasis except regional lymphnodes. Intra M et al, in their prospective study of 143 cases with SBBC, showed that there is a strong correlation of extensive intraductal component between the bilateral breast tumours which implies independent tumours and excludes the metastatic origin of these tumours.[4]

Patients with bilateral breast carcinoma who present with synchronous disease are at greater risk of distant metastasis than women with unilateral or metachronous breast tumours. There is decreased overall survival and local control for patients with synchronous bilateral carcinoma compared to patients with metachronous or unilateral disease.[5,6] Prognosis also seems to be poor when the second tumour appeared within 2 yrs after onset of the index cancer. The longer the interval between the diagnoses of the two cases, the better is the survival rate.[7,8,9,10]

Optimal surgical management of these primary synchronous breast carcinoma is controversial. In the past these cases were treated more aggressively with bilateral MRMs with the view that the disease has poor survival and outcome. Gollamuddie et al showed that early stage SBBC can be safely treated with bilateral breast conservative surgery with outcome that appears to be comparable to that of patients with early stage unilateral breast carcinoma.[11,2]

Treatment of second breast cancer is similar to treatment of first tumour. Treatment should be appropriate for the stage of disease. Indications for complementary systemic treatment or radiotherapy are the same in the first and second breast cancer.

**CONCLUSION:** Although the occurrence of synchronous bilateral carcinoma breast is rare, the condition should be kept in mind and the contralateral breast should be subjected to triple assessment at the time of diagnosis of the index tumour. Thereafter the contralateral breast should be followed up by clinical examination 6 monthly and mammography yearly.

As the condition is rare, multi-institutional, prospective studies with longer follow-up are needed for better understanding the synchronous bilateral breast carcinoma.
CASE REPORT

BIBLIOGRAPHY:
CASE REPORT

Fig. 3

Fig. 4: HPE- Invasive duct cell carcinoma right breast with insitu component

Fig. 5: HPE- Invasive ductal Carcinoma left breast

AUTHORS:
1. A. Ravikamal Kumar
2. S. V. P. L. Chandrakumar

PARTICULARS OF CONTRIBUTORS:
1. Associate Professor, Department of General Surgery, Guntur Medical College, Guntur.
2. Assistant Professor, Department of General Surgery, Guntur Medical College, Guntur.

FINANCIAL OR OTHER COMPETING INTERESTS: None

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. A. Ravikamal Kumar,
Flat No. 10, Garudadri Towers,
Mahakavi Sri Sri Street,
Maruthi Nagar,
Guntur-522006.
E-mail: ravikka@rediffmail.com

Date of Submission: 24/02/2015.
Date of Peer Review: 25/02/2015.
Date of Acceptance: 14/03/2015.
Date of Publishing: 26/03/2015.